Gastro-entero-pancreatic tumors comprise a group of heterogenous neoplasms, with medical imaging being paramount in the diagnosis, staging, and treatment planning of these tumors. Moreover, with the advent of newer radiopharmaceuticals, such as 68 Ga-labeled and 64 Cu-labeled somatostatin analogs (eg, 68 Ga-DOTATOC, 68 Ga-DOTATATE, 68 Ga-DOTANOC, and 64Cu-DOTATATE) that bind to the somatostatin receptor (SSTR), molecular imaging plays an increasing and critical role in the diagnosis, staging, and treatment planning of these neoplasms. Dual-tracer imaging with 18F-FDG PET/CT and SSTR agents may play a significant role in treatment planning and predicting patient outcomes in the setting of high-grade or poorly differentiated neuroendocrine tumors.
Keywords: (18)F-FDG PET/CT; (64)Cu-DOTATATE PET/CT; (68)Ga-DOTATATE PET/CT; Gastro-entero-pancreatic neoplasms; Ki-67 proliferative index; Poorly differentiated neuroendocrine tumors; Well-differentiated neuroendocrine tumors.
Copyright © 2022 Elsevier Inc. All rights reserved.